natgillin/translations-raw huggingface dataset:
Conveniently the reaction is carried out at low temperatures e.g. approximately −78 C. The mixed anhydride is conveniently prepared by reacting the carboxylic acid (11) with a suitable acid chloride e.g. pivavolyl chloride in an aprotic solvent such as ethyl acetate in the presence of a tertiary organic base such as a trialkylamine e.g. triethylamineand at low temperatures e.g. approximately −78 C. 
Reakciju se pogodno provodi na niskim temperaturama, primjerice približno -78 *C. Miješani anhidrid se pogodno dobije reakcijom karboksilne kiseline (11) s pogodnim kiselinskim kloridom, primjerice pivalolil-kloridom, u neprotonskom otapalu, poput etil-acetata, u prisutnosti tercijarne organske baze, poput trialkilamina, primjerice trietilamina, na niskim temperaturama, primjerice približno -78 C.
displacing the puncturing member (323) whereby said seal (22) is broken and the preserving agent is allowed to enter into the container (1) through the separator (31). 
izmiještanja elementa (323) za probijanje čime se probija navedeni element (22) za zaptivanje i omogućava da se sredstvo za prezervaciju uzorka ulije u posudu (1) kroz separator (31).
and R4 together with the carbon atom to which they are bonded form a C3- or C4-ring, or 
Ri R* zajedno s atomom ugljika na koji su povezani tvore skupinu formule C=CR""R", gdje
For example, the compounds of Formula II may be prepared in accordance with Reaction Scheme 1: 
Na primjer, spojevi prikazani Formulom II mogu se pripraviti u skladu sa reakcijskom Shemom 1:
List of the reference numerals used: 
Datum podnošenja europske prijave patenta:
Y represents two hydrogen atoms, or an oxygen atom; and/or 
Y predstavlja dva atoma vodika ili atom kisika;
The chimeric protein according to any one of claims 1 or 2, wherein said heterologous polypeptide comprises or consists of, from N-terminal to C terminal, the C-terminal part of the E7 protein of a first HPV type, the C-terminal part of the E7 protein of a second HPV type, the C-terminal part of the E7 protein of a third HPV type, optionally the C-terminal part of the E7 protein of a fourth HPV type, the N-terminal part of the E7 protein of said first HPV type, the N-terminal part of the E7 protein of said second HPV type, the N-terminal part of the E7 protein of said third HPV type, and optionally the N-terminal part of the E7 protein of said fourth HPV type. 
Kimerni protein u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što navedeni heterologni polipeptid sadrži ili se sastoji od, od N-kraja do C-kraja, C-terminalnog dijela proteina E7 iz prvog tipa HPV-a, C-terminalnog dijela proteina E7 iz drugog tipa HPV-a, C-terminalnog dijela proteina E7 iz trećeg tipa HPV-a, izborno C-terminalnog dijela proteina E7 iz četvrtog tipa HPV-a, N-terminalnog dijela proteina E7 iz navedenog prvog tipa HPV-a, N-terminalnog dijela proteina E7 iz navedenog drugog tipa HPV-a, N-terminalnog dijela proteina E7 iz navedenog trećeg tipa HPV-a, te izborno N-terminalnog dijela proteina E7 iz navedenog četvrtog tipa HPV-a.
A recombinant AAV vector comprising a transgene encoding acid sphingomyelinase for use in a method of treating Niemann-Pick A disease or Niemann-Pick B disease in a subject, wherein said recombinant AAV vector is an AAV5 vector and wherein the method comprises administering the vector to at least one ventricle of the brain of the subject, whereby said transgene is expressed and the expressed protein product is delivered to the central nervous system and, optionally, to visceral organs. 
Rekombinantni AAV vektor koji sadrži transgen kodira kiselinu sfingomijelinazu za upotrebu u postupku liječenja Niemann–Pickove bolesti tip A ili Niemann–Pickove bolesti tip B kod subjekta, naznačen time da navedeni rekombinantni AAV vektor je AAV5 vektor i pri čemu postupak sadrži davanje vektora u barem jednu ventrikulu mozga od subjekta, pri čemu se navedeni transgen eksprimira i eksprimirani proizvod proteina se dovodi u središnji živčani sustav, te proizvoljno, u visceralne organe.
Later, a new copy is made in a second database (13) and it is sent to the certification system's outgoing mail server (14). 
- < slanje od odlaznog poslužitelja pošte (14) druge elektronske pošte koja sadrži presliku elektronske pošte s određenom oznakom,
• means for determining and adjusting the flow-rates of the gases that enter the mixing system (1), said gases being one or more of nitrogen, carbon dioxide, nitrous oxide, oxygen and hydrocarbon, as a function of the type of thermal treatment and of the concentration of carbon monoxide, carbon dioxide, methane and nitrous oxide and optionally of the dew point and/or of the concentration of oxygen, and of the temperature in the treatment furnace, as detected, and 
sredstva za određivanje i prilagođavanje protoka plinova koji ulaze u sustav miješanja (1), pri čemu su navedeni plinovi jedan ili više između dušika, ugljičnog dioksida, dušikovog oksida, kisika i ugljikovodika, kao funkcija vrste toplinske obrade i koncentracije ugljikovog monoksida, ugljičnog dioksida, metana i dušikovog oksida 1 po izboru točke rosišta i / ili koncentracije kisika i temperature u peći za obradu, kako je izmjereno i -
Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and/or salts and/or hydrates and/or solvates and/or polymorphs thereof for use in a method of treating schizophrenia with the therapeutically effective amount of 1.5, 3.0 or 4.5 mg/day. 
Spoj, naznačen time, da je to trans-4-(2-[4-(2,3-diklorofenil)-piperazin-1-il]-etilj-N,N-dimetilkarbamoilcikloheksilamin i/ili njegove soli i/ili njegovi hidrati i/ili solvati i/ili polimorfi, koji su za uporabu u postupku liječenja shizofrenije s terapeutski učinkovitom količinom od 1,5; 3,0 ili 4,5 mg na dan.
An apparatus for production of a biogas by anaerobic digestion of organic material, the apparatus comprising: 
Uređaj za proizvodnju bioplina anaerobnom razgradnjom organskog materijala, uređaj sadrži: spremnik digestije koji ima:
wherein one separating plate (4) of the seeding heart (1) has a hub element or a flange surface for holding a drive flange and an opposite plate (5) has an opening for building up a pressure difference. 
Srce za sijanje u skladu sa patentnim zahtjevom 1 ili 2, naznačeno time da jedna ploča (4) za odvajanje srca (1) za sijanje ima središnji element ili bočnu površinu za držanje pogonskog krila 1 da suprotna ploča (5) ima otvor za razvijanje razlike u pritisku.
A compound according to claim 1, or salt or solvate thereof, wherein said compound is selected from the group consisting of: 
Spoj, ili njegova sol ili solvat, naznačen time što se navedeni spoj bira iz skupine koju čine:
O═R1 (VIIa) wherein R1 represents a —(C(R3)2)n-heterocycloalkyl group, in which the heterocycloalkyl group may be optionally substituted by at least one substituent selected from a halogen, C1-3-alkyl, C1-3-alkoxy, C1-3-haloalkoxy or C1-3-haloalkyl and contains at least one oxygen atom, and n=0. A pharmaceutical composition comprising at least one compound of claim 1, pharmaceutically acceptable salts, prodrugs, isomers or solvates thereof, and at least a pharmaceutically acceptable carrier, additive, adjuvant or vehicle. 
O=RI1 (VIIa) gdje R, predstavlja a- (C(R3)),- heterocikloalkilna skupina proizvoljno supstituirana s najmanje jednim supstituentom odabranim između halogena, Ci. -alkila, Cy3-alkoksi, Ci3-haloalkoksi ili Cy3-haloalkil i sadrži najmanje jedan atom kisika in = 0. Farmaceutski pripravak, naznačen time, da sadrži najmanje jedan spoj kako je definiran u bilo kojem od patentnih zahtjeva 1-7 ili njegovu farmaceutski prihvatljivu sol ili solvat, te farmaceutski prihvatljiv nosač, aditiv, adjuvans ili prijenosnik.
The method of claim 1, wherein the neuron injury occurs in neuron damage caused by hypoxia. 
5o-androstan-3B,5,6f-triol za uporabu u skladu s patentnim zahtjevom 1, pri čemu je oštećenje neurona uzrokovano hipoksijom.
a light chain comprising an amino acid sequence provided as SEQ ID NO: 23, or a deaminadated and/or oxidized variant thereof; and 
slabi lanac koji sadrži aminokiselinsku sekvencu danu kao SEQ ID NO:23 ili njezinu deamidiranu i/ili oksidiziranu varijantu; i
The method according to any one of claims 6 to 8, further comprising: in the uplink synchronous status, not resetting a timer based on the timing deviation information included in the random access response (S02), wherein the uplink status is maintained until the timer expires. 
provodi usklađivanje vremena uzlazne veze na temelju informacije o odstupanju sinkronog vremena, u slučaju da je, kod asinkronog statusa uzlazne veze, informacija o odstupanju sinkronog vremena uključena u odgovor sa slučajnim pristupom (S02);
Synthesis of a Representative Bilayer Tablet of the Invention 
Datum podnošenja europske prijave patenta:
A sample of the crystalline material was shaken in a separating funnel with excess saturated aqueous sodium carbonate and dichloromethane. 
Primjerak kristaliničnog materijala se protrese u lijevku za odijeljivanje sa suviškom zasićenog vodenog natrij karbonata 1 diklorometana.
Another embodiment is the N-2 Form characterized by (or having) a powder x-ray diffraction pattern further comprising four or more of 2θ values (CuKa λ=1.5418 Å) selected from 5.5, 9.1, 12.1, 14.0 and 19.2 at a temperature of about 22° C. 
Kristalni oblik prema zahtjevima 1-4, dalje naznačen time što obrazac difrakcije rendgenskog zračenja na prašku obuhvaća četiri ili više 20 values (CuKa 2=1.5418 A) izabrane između 5.5, 9.1, 12.1, 14.0 i 19.2 pri temperaturi od oko 22*C.
2A: Gene sequence of Anabaena variabilis PAL (SEQ ID NO:3); FIG. 
Farmaceutski sastav iz patentnog zahtjeva 1, pri čemu AvPAL ima slijed SEQ ID NO: 11.
A conjugated polymer prepared by the method according to claim 1, wherein the conjugated polymer absorbs radiation within a first band of the visible spectrum and a second band of the visible spectrum and is green in the neutral state and upon oxidation the conjugated polymer is in a transmissive state with absorbance of radiation within the first and second bands being less than in the neutral state. 
Konjugirani polimer pripremljen postupkom prema zahtjevu 1, gdje konjugirani polimer apsorbira zračenje iz prve vrpce vidljivog spektra i druge vrpce vidljivog spektra i zelen je u neutralnom stanju, a nakon oksidacije polimer je u propusnom stanju s apsorbiranjem zračenja unutar prve i druge vrpce koje je manje nego u neutralnom stanju.
The invention also provides compounds of the formula (VIII) or (IX) in which R1 and R2 together with the nitrogen atom to which they are attached form an azetidine, where the azetidine has two substituents which, together with the carbon atom of the azetidine to which they are jointly attached, form an oxetane, and R5 represents C1-C4-alkyl, preferably methyl or ethyl, and the salts thereof, the solvates thereof and the solvates of the salts thereof. 
Spoj s formulom (VIII) ili (IX) u kojoj R' i R* zajedno s dušikovim atomom na koji su oni vezani tvore azetidin, gdje azetidin ima dva supstituenta koji, zajedno s ugljikovim atomom 1z azetidina na koji su zajednički vezani, tvore oksetan, i R predstavlja C,-C;-alkil, poželjno metil ili etil, i njegove soli, njegovi solvati i solvati njegovih soli.
cardiovascular agents, lipid lowering agents, anti-diabetic agents e.g. PPAR-gamma activators e.g. rosiglitazone or pioglitazone, anti-epileptics, anti-infectives (including antibiotics for example, lantibiotics and bacteriocins), anti-fungal agents, anti-viral agents, antipsychotic agents, immunosuppressants, protease inhibitors and cyclic peptides; and 
kardiovaskularnih sredstava, sredstava za snižavanje lipida, sredstava protiv dijabetesa npr PPAR-gama aktivatora npr. rosiglitazon ili pioglitazon, antiepileptika, anti-infektiva (uključujući, na primjer, antibiotike i lantibiotike i bakteriocine), antifungalnih sredstava, antivirusnih sredstava, antipsihotika, imunosupresiva, proteaza i cikličkih peptida; i
The compound of claim 4, wherein the compound is represented by the following structural formula: 
Spoj sukladno zahtjevu 1, naznačen time, da je spoj predstavljen slijedećom strukturnom formulom:
Other types of connector, than that shown, are possible within the scope of the invention. 
Ostale vrste konektora, uz one prikazane, su moguće u okviru duha izuma.
reducing the dosage or dose frequency of said P-gp inhibitor or avoiding completely the administering of said P-gp inhibitor before starting of administering BIBW 2992 or a pharmaceutically acceptable salt thereof, and 
smanjivanje doze ili učestalosti doziranja navedenog P-gp-inhibitora ili potpuno izbjegavanje davanja navedenog P-gp-inhibitora prije početka davanja BIBW 2992 ili njegove farmaceutski prihvatljive soli, i
q ranges from 1 to 4, and Ab is an antibody as specified in the claims 
E O q je u rasponu od 1 do 4, a Ab je protutijelo ili njegov fragment ili derivat.
that the suspension device (1) also comprises a second spring member (5b) acting between the gripping shanks, against the action of which the gripping shanks (10, 20) are pivotable from the closed position towards the open position; and 
- < naprava za vješanje (1) također obuhvaća drugi opružni element (5b), koji djeluje između steznih držača, a nakon njegovog djelovanja stezni držači (10, 20) okretno se pomiču iz zatvorenog položaja prema otvorenom položaju, te
The composition of any one of the preceding clauses wherein the acidic variants include glycated variant, deamidated variant, disulfide reduced variant, sialylated variant, and non-reducible variant. The composition of any one of the preceding clauses wherein the amount of the acidic variants is less than about 25%. 
Sastav prema zahtjevu 1, naznačen time, da kiselinske varijante nadalje obuhvaćaju glikoziranu varijantu, Sastav prema zahtjevu 1 ili zahtjevu 2, naznačen time, da količina kiselinskih varijanti iznosi manje od 25%.
A fixed dose combination of any of claims 1 to 7 which contains 5 mg pimobendan and 10 mg benazepril, and has a width of 10 to 10.5 mm, a length of 19 to 19.5 mm and a thickness of 6.5 to 7.5 mm. 
Kombinacija s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što sadrži 5 mg pimobendana i 10 mg benazeprila, te ima širinu od 10 do 10,5 mm, duljinu od 19 to 19,5 mm i debljinu od 6,5 do 7,5 mm.
a combination of at least one 1-arylpyrazole active agent of formula (I), wherein: 
kombinacija od najmanje jedne djelatne tvari 1-arilpirazola sa sljedećom formulom (I):
Use of a compound or a pharmaceutically acceptable salt according to any of claims 1 to 8 or a pharmaceutical composition thereof in the manufacture of a medicament for treating an inflammatory or immune-related physiological disorder, symptom or disease. 
Primjena spojeva ili farmaceutski prihvatljive soli prema bilo kojem od patentnih zahtjeva 1 do 18 ili njegove farmaceutske kompozicije, naznačena time što se koristi u proizvodnji lijeka za liječenje inflamatornog ili fiziološkog poremećaja, simptoma ili bolesti povezanih sa imunološkim sustavom,
An immunoconjugate comprising the cysteine engineered antibody of claim 11 covalently attached to a cytotoxic agent, wherein optionally the cytotoxic agent is selected from a toxin, a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme. 
Imunokonjugat, naznačen time, da obuhvaća protutijelo genetskog inženjeringa cisteinom prema zahtjevu 11, kovalentno priključeno na citotoksično sredstvo, pri čemu je to citotoksično sredstvo po želji odabrano od sljedećih: toksin, kemoterapeutsko sredstvo, skupina ljekovitog sredstva, antibiotik, radioaktivni izotop i nukleolitički enzim.
at least one pump; 
- barem jednu pumpu;
The method as claimed in claim 1 or 2, in which said tumor-associated antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 29. 
Farmaceutski pripravak radi primjene sukladno zahtjevu 1 ili 2, pri čemu antigen povezan s tumorom ima aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEQ ID NO: 2, 58, 59, 60, 68 i 69.
A therapeutic or prophylactic agent for gastroesophageal reflux disease, functional dyspepsia, irritable bowel syndrome, diabetic gastroparesis, constipation, opioid-induced bowel dysfunction, paralytic ileus, or postoperative gastrointestinal paralysis, comprising the compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 25 as an active ingredient. 
Lijek prema patentnom zahtjevu 27, za uporabu kao terapeutsko ili profilaktičko sredstvo za gastroezofagealnu refluksnu bolest, funkcionalnu dispepsiju, sindrom iritabilnog crijeva, dijabetičku gastroparezu, konstipaciju, opioidom-induciranu disfunkciju crijeva, paralitički ileus ili postoperativnu gastrointestinalnu paralizu.
Use according to anyone of claims 24 to 26 wherein said medicament is for treating and/or preventing inflammatory conditions, rheumatoid arthritis, asthma, psoriasis, myocarditis, atopic dermatitis, lymphocytic leukemias, lymphomas, multiple sclerosis, lupus erythematosus, inflammatory bowel diseases. 
Upotreba prema bilo kojem od patentnih zahtjeva 20 do 22, gdje navedeni lijek je namijenjen liječenju i/ili sprječavanju upalnih stanja, reumatoidnog artritisa, astme, psorijaze, miokarditisa, atopičnog dermatitisa, limfocitnih leukemija, limfoma, multiple skleroze, eritematoznog lupusa, te upalnih bolesti crijeva.
The length of the tube is at least approximately 15 cm. 
Duljina cijevi je najmanje približno 15 cm.
This article is provided with a cellulose acetate tube 40, in place of the foil lined tube of previous embodiments. 
Ovaj proizvod je osiguran sa cjevi 40 od acetata celuloze, umjesto cjevi koja je obložena folijom iz prethodnih realizacija.
a flexible conduit (70) for delivering the atomized treatment product (52) from the container (54) to the closed mechanical system; and 
(b) savitljivu vodilicu (70) za dovođenje atomiziranog sredstva za obradu (52) iz spremnika (54) u zatvoreni mehanički sustav; te
The offshore aquaculture system of claim 1, wherein the positioning apparatus is arranged to mechanically remove foulants from the framework upon movements of the cages with respect to the framework. 
Sustav odobalne akvakulture prema zahtjevu 1, pri čemu je uređaj za pozicioniranje (140) postavljen tako da može mehanički odstraniti obrasline s okvira (120) nakon što se rešetke (130) pomaknu u odnosu na okvir (120).
Various dry powder inhalers suitable for dry powder are already described in the prior art, e.g. 
Različiti inhalatori sa suhim prahom prikladni za suhi prah su već opisani u stanju tehnike, npr.
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use according to claim 1, wherein the LSD is chosen from Tay-Sachs disease, the AB variant of Tay-Sachs disease, Sandhoff disease, Niemann-Pick type A disease, Niemann-Pick type B disease, Fabry disease, neuronal ceroid lipofuscinoses, Krabbe disease, Farber disease, Gaucher disease, metachromatic leukodystrophy, multiple sulphatase deficiency, mucolipidosis II, mucolipidosis III, MPS III, MPS VII, GM1 gangliosidosis, and aspartylglucosaminuria. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema zahtjevu 1, pri čemu je LSD odabran od Tay-Sachsove bolesti, AB varijante Tay-Sachsove bolesti, Sandhoffove bolesti, Niemann-Pick bolesti tipa A, Niemann-Pick bolesti tipa B, Fabryjeve bolesti, neuronske ceroidne lipofuscinoze, Krabbove bolest, Farberove bolesti, Gaucherove bolesti, metakromatske leukodistrofije, multiple deficijencije sulfataze, mukolipidoze II, mukolipidoze III, MPS III, MPS VII, GMI gangliozidoze i aspartilglukozaminurije.
The composition of any one of claims 1 to 7, wherein said composition is for administration every 12 hours. 
Sastav prema bilo kojem od zahtjeva 1 do 8, naznačen time da je spomenuti sastav za primjenu svakih 12 sati.
Aqueous dilution preparation derived from the aqueous preparation according to claim 1, wherein the aqueous preparation is diluted 1:2 to 1:8. 
Postupak pripreme vodenog pripravka prema zahtjevu 8, gdje je vodeni pripravak razrijeđen 1:2 do 1:8.
The method according to claim 1, wherein the mobile message is selected from group consisting of: a message of short messaging service; multimedia messaging service; picture messaging service; and mobile instant messaging service. 
Postupak prema bilo kojem od prethodnih zahtjeva, gdje se poruka odabire iz grupe koja obuhvaća: poruku iz usluge kratkih poruka; uslugu multimedijalnih poruka; uslugu slanja slika; 1 uslugu mobilnih instant poruka.
The reaction is catalyzed using a palladium catalyst, PdLn, wherein L is a ligand selected from PR'3 wherein R' is selected from alkyl, aryl, alkylaryl, and NR"3 wherein R" is selected from alkyl, aryl, and alkylaryl. 
L se bira iz skupine koju čine PR! i NR",, gdje R' se bira iz skupine koju čine alkil, aril, alkilaril, a R" se bira iz skupine koju čine alkil, aril, i alkilaril;
This object is achieved by a vaccine comprising a multiplicity (more than one, at least two) of fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein a first fragment of said at least two fragments comprises at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and a second fragment of said at least two fragments comprises at least 8 consecutive amino acid residues of amino acid residues 205 to 225 of PCSK9 (SEQ ID NO: 9). 
PATENTNI ZAHTJEVI Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 153 do 165 od PCSK9 u skladu sa SEQ ID NO:9,1 gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 209 do 222 od PCSK9 u skladu sa SEQ ID NO:9.
The method according to claim 3, wherein agomelatine is added to an aqueous organic solvent containing HCl to precipitate a crystal of the product. 
Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 3, naznačen time, da se agomelatin dodaje vodenom organskom otapalu koje sadrži HCI da se istaloži kristal proizvoda.
The pregnenolone derivative compound according to claims 1 or 2, wherein said compound is of formula (D): or a pharmaceutically acceptable salt thereof, wherein 
Tvar derivat pregnenolona u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedena tvar formule (D):
A compound having the formula: for use in a method of treating an opioid toxicity or overdose in a subject in need thereof comprising administrating a first opioid receptor antagonist followed by the compound. 
Spoj koji sadrži formulu: d Ket za uporabu u postupku liječenja opioidne toksičnosti ili predoziranja kod subjekta kojem je potrebno sadrži isporuku prvog antagonista receptora opioida nakon čega slijedi taj spoj.
The intragastric balloon of claim 1, wherein the expandable foaming substances are mixed using a baffle mixer. 
Intragastrički balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu se te tvari miješaju korištenjem pregradne mješalice (48).
splitting an excess steam from at least one position within the recirculation circuit; 
podjela viška pare (7) s barem jednog položaja unutar recirkulacijskog kruga,
Date of onset; 
Datum međunarodne objave:
reacting a compound of Formula XII with a compound of Formula XXI to give a compound of Formula XXII; hydrogenating the compound of Formula XXII to give a compound of Formula XXIII; 
Formula XXII čime se dobiva spoj Formule XXII: b. hidrogeniranje spoja Formule XXII, čime se dobiva spoj Formule XXIII: a. H o '
According to formula (1), R4q is suitably phenyl substituted by OH, C(=NH)NH2, or S02NH2. 
1. Spoj, naznačen time, da ima formulu (1), ili njegovi stereoizomeri ili njegove farmaceutske prihvatljive soli, a2 R
• are shaped in suitable profiles having high aerodynamic efficiency, 
oblikovane u pogodne profile visoke aerodinamičke djelotvornosti, .
Pharmaceutical compositions and methods for producing low impurity concentrations of the same 
FARMACEUTSKI SASTAV CLEVIDIPINE-A I METODE ZA PROIZVODNJU ISTIH SA NISKIM KONCENTRACIJAMA NEČISTOĆA